Pharmaceutical Technology, Sep 1, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Sep 1, 2013
Featured Content
Gaining Insights on Contract Chemical API Manufacturing
By Patricia Van Arnum
Industry experts share their views on the outsourcing model and the current and future direction of contract chemical API manufacturing.
Optimizing Quality by Design in Bulk Powders and Solid Dosage
By Conrad Winters , Filipe Neves
Case studies on the manufacture of a bluk powder and the development of a tablet show the application of QbD principles.
Coating and Taste Masking with Shellac
By Beverly Schad , Brian Cheng , Eric Van Ness , Tom Riley , Jeff Scholten , Houston Smith
The authors describe the background and applications of fully formulated aqueous shellac for film-coating systems.
Risk Assessment of Excipients
By Patricia Van Arnum
Industry experts share perspectives on risk assessment and mitigation in excipient manufacture and the excipient supply chain.
Making the Best of a Bad CMO-Client Relationship
By Eric Langer
A CMO perspective on the CMO-client partnership.
Examining the Role of Cocrystals in Drug Development and Manufacturing
By Cynthia Challener, PhD
A recent FDA guidance places greater attention on cocrystals as a tool in solid-dosage formulation.
Advancing API Synthesis
By Cynthia Challener, PhD
Commercial-scale amide formation and an improved process route for a tetracycline derivative are some recent developments in API synthesis.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here